Develops Zorifertinib, a next-generation EGFR tyrosine kinase inhibitor designed to treat advanced non-small cell lung cancer with central nervous system metastases, achieving 100% blood-brain barrier penetration. This first-in-class therapy addresses the unmet need for effective treatments in patients with brain metastases, supported by funding from national drug innovation programs.

JUMPCODE offers CRISPR-mediated rRNA depletion kits, including DepleteX™ and CRISPRclean®, that enhance next-generation sequencing (NGS) workflows by removing uninformative nucleic acids. This technology improves sensitivity and data quality across various genomic applications, including single-cell analysis and microbiome characterization.

Mojia Bioscience employs bio-manufacturing techniques to create sustainable materials that significantly reduce carbon emissions in industrial processes. The company provides carbon-neutral alternatives to traditional manufacturing, contributing to sustainable development and minimizing environmental impact.

Qpex Biopharma develops therapeutic agents that target antibiotic-resistant infections and viral diseases through advanced drug discovery techniques. The company focuses on providing effective treatments to combat the growing threat of infectious pathogens worldwide.

Wugen is developing off-the-shelf allogeneic cellular therapies, including CAR-T and NK cell treatments, specifically targeting solid tumors and hematologic malignancies. These therapies aim to provide effective treatment options for patients with relapsed or refractory cancers, utilizing engineered cells derived from healthy donors to enhance therapeutic efficacy.